Multiple sclerosis (MS) is the most common chronic demyelinating disease of the central nervous system of unknown and probable autoimmune etiology. MS is a lifelong illness which have a significant impact on quality of life. Multiple sclerosis affects mainly young adults, therefore, is an important public health issue. The analysis of direct and indirect costs associated with MS showed that the disease generates significant costs to the Polish health care system in analyzed period (2013–2015). Costs related to the reimbursement of treatment in the drug programs in 2015 could reach nearly 300 million PLN and indirect costs in 2013 amounted to nearly 60 million PLN. Analysis of recommendations of chosen HTA agencies world‑wide was performed to provide a review of status of SM drugs in this matter.

Key words: MS, multiple sclerosis, direct costs, indirect costs, NFZ.